Compare Wockhardt with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs TORRENT PHARMA - Comparison Results

WOCKHARDT     Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT TORRENT PHARMA WOCKHARDT/
TORRENT PHARMA
 
P/E (TTM) x -18.9 56.9 - View Chart
P/BV x 1.0 6.0 16.6% View Chart
Dividend Yield % 0.0 0.9 0.5%  

Financials

 WOCKHARDT   TORRENT PHARMA
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
TORRENT PHARMA
Mar-18
WOCKHARDT/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0121,550 65.3%   
Low Rs5321,144 46.5%   
Sales per share (Unadj.) Rs355.9354.7 100.3%  
Earnings per share (Unadj.) Rs-60.340.1 -150.4%  
Cash flow per share (Unadj.) Rs-46.864.2 -72.8%  
Dividends per share (Unadj.) Rs0.0114.00 0.1%  
Dividend yield (eoy) %01.0 0.1%  
Book value per share (Unadj.) Rs257.8273.1 94.4%  
Shares outstanding (eoy) m110.63169.22 65.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.23.8 57.1%   
Avg P/E ratio x-12.833.6 -38.1%  
P/CF ratio (eoy) x-16.521.0 -78.7%  
Price / Book Value ratio x3.04.9 60.7%  
Dividend payout %034.9 -0.0%   
Avg Mkt Cap Rs m85,379227,897 37.5%   
No. of employees `0006.314.7 42.5%   
Total wages/salary Rs m9,37111,353 82.5%   
Avg. sales/employee Rs Th6,295.04,083.0 154.2%   
Avg. wages/employee Rs Th1,498.3772.3 194.0%   
Avg. net profit/employee Rs Th-1,066.3461.3 -231.1%   
INCOME DATA
Net Sales Rs m39,36960,021 65.6%  
Other income Rs m1,2022,988 40.2%   
Total revenues Rs m40,57163,009 64.4%   
Gross profit Rs m1813,493 0.1%  
Depreciation Rs m1,4954,086 36.6%   
Interest Rs m2,5553,085 82.8%   
Profit before tax Rs m-2,8309,310 -30.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5820-   
Tax Rs m2572,529 10.2%   
Profit after tax Rs m-6,6696,781 -98.3%  
Gross profit margin %022.5 0.2%  
Effective tax rate %-9.127.2 -33.4%   
Net profit margin %-16.911.3 -149.9%  
BALANCE SHEET DATA
Current assets Rs m33,79652,623 64.2%   
Current liabilities Rs m26,91752,022 51.7%   
Net working cap to sales %17.51.0 1,743.5%  
Current ratio x1.31.0 124.1%  
Inventory Days Days79120 66.3%  
Debtors Days Days8976 117.1%  
Net fixed assets Rs m39,66485,016 46.7%   
Share capital Rs m553846 65.4%   
"Free" reserves Rs m27,96845,376 61.6%   
Net worth Rs m28,52246,222 61.7%   
Long term debt Rs m21,73141,115 52.9%   
Total assets Rs m81,620142,432 57.3%  
Interest coverage x-0.14.0 -2.7%   
Debt to equity ratio x0.80.9 85.7%  
Sales to assets ratio x0.50.4 114.5%   
Return on assets %-5.06.9 -72.8%  
Return on equity %-23.414.7 -159.4%  
Return on capital %-7.714.2 -54.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,80714,580 67.3%   
Fx outflow Rs m1,7893,600 49.7%   
Net fx Rs m8,01910,980 73.0%   
CASH FLOW
From Operations Rs m6848,942 7.7%  
From Investments Rs m6,302-47,070 -13.4%  
From Financial Activity Rs m-7,69534,174 -22.5%  
Net Cashflow Rs m-664-3,655 18.2%  

Share Holding

Indian Promoters % 74.5 71.5 104.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 7.0 32.8%  
FIIs % 7.7 12.6 61.1%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 8.8 175.0%  
Shareholders   67,757 26,511 255.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  PROCTER & GAMBLE HEALTH  

Compare WOCKHARDT With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Bajaj Finance and ICICI Bank Top Gainers(12:30 pm)

Stock markets in India are presently trading on a positive note. The BSE Sensex is trading up by 90 points and the NSE Nifty is trading up by 35 points.

Related Views on News

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Oct 16, 2019 12:53 PM

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE WOCKHARDT WITH

MARKET STATS